Perifosine

Generic Name: Perifosine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₅₂NO_₄P

CAS Number: 157716-52-4

Unique Ingredient Identifier: 2GWV496552

Background: Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.

Indication: Investigated for use/treatment in solid tumors, multiple myeloma, leukemia (unspecified), lung cancer, and brain cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Perifosine in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-10-08

Last Posted Date: 2019-12-13

Lead Sponsor: University of Wisconsin, Madison

Registration Number: NCT00005794

Locations: 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States

Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Recurrent Adult Soft Tissue Sarcoma
Stage III Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions: Drug: perifosine
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-07-09

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00064324

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: perifosine

First Posted Date: 2003-06-06

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00062387

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States

and more 9 locations

Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2003-05-07

Last Posted Date: 2013-06-24

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00059982

Locations: 🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸
Tufts - New England Medical Center, Boston, Massachusetts, United States
🇺🇸
CCOP - Duluth, Duluth, Minnesota, United States

and more 7 locations

Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-05-07

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00060437

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Perifosine in Treating Patients With Recurrent Prostate Cancer

Phase 2

Terminated

Conditions: Recurrent Prostate Cancer
Stage IIB Prostate Cancer
Stage III Prostate Cancer
Stage IV Prostate Cancer
Adenocarcinoma of the Prostate

Interventions: Drug: perifosine
Other: laboratory biomarker analysis

First Posted Date: 2003-04-09

Last Posted Date: 2015-02-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00058214

Locations: 🇺🇸
UC Davis Cancer Center, Sacramento, California, United States

Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-02-06

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 18

Registration Number: NCT00053781

Locations: 🇨🇦
Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada
🇨🇦
Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada

and more 3 locations

Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-02-06

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00054145

Locations: 🇨🇦
Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada
🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada

and more 1 locations

Perifosine in Treating Patients With Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2003-02-06

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00053924

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada

Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Sarcoma
Endometrial Cancer

First Posted Date: 2003-02-06

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 17

Registration Number: NCT00053794

Locations: 🇨🇦
Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada
🇨🇦
Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada
🇨🇦
Mount Sinai Hospital - Toronto, Toronto, Ontario, Canada

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy